Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Invests In Hearing-Drug Firm Audion
by Lisa M. Jarvis
February 17, 2014
| A version of this story appeared in
Volume 92, Issue 7
Eli Lilly & Co. has taken a stake in Audion Therapeutics, a biotech firm with labs in Cambridge, Mass., focused on diseases that affect the ear. As part of the deal, Audion gains the rights to several Lilly compounds intended to treat hearing loss using hair-cell regeneration. Lilly has an option to reacquire the drugs after they have gone through human testing. In the past year, Lilly has brought back in-house two compounds it had licensed out: a diabetes drug from Transition Therapeutics and a migraine treatment from Arteaus Therapeutics.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter